In this month’s issue of The Oncology Pharmacist (TOP), we continue our coverage of the news from the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) by addressing the topic of chemotherapy dosing for patients who are obese.
In this month’s issue of The Oncology Pharmacist (TOP), we explore the growth of specialty pharmacies and the implications for our relationship with patients. Author Lea Ann Hansen discusses the evolution of specialty pharmacy and the function it serves in the treatment of cancer and how this affects patients. As Hansen points out in her article, “In many cases, the complicated nature of administration or possible adverse events with specialty drugs necessitate intensive patient monitoring.”
It was on the front page of my newspaper. It is in the data services I subscribe to for the American Society of Health-System Pharmacists and the American Society of Clinical Oncology. It is the feature of a new survey from the Hematology Oncology Pharmacy Association and is the lead-in for the Pharmacists’ Newsletter. It is on the nightly news, and it was explored in depth in the last issue of the Journal of Hematology Oncology Pharmacy (JHOP).